Zoltan Mari, MD
Assistant Professor of Neurology
Director, Movement Disorder Fellowship Training Program
Director, Dystonia and Chemodenervation Center
Director, National Parkinson Foundation Center of Excellence
Director, Deep Brain Stimulation Center
Johns Hopkins University
Elizabeth Ann Moberg-Wolff, MD, FAAPMR
Pediatric Rehabilitation Medicine Associates, LLC
Mobile + Online on RealCME
Spasticity is a common chronic condition that is estimated to affect over half a million persons in the US. The etiologies of spasticity are heterogeneous and include neurologic disorders such as cerebral palsy and multiple sclerosis, as well as physical insults to the central nervous system seen with strokes and traumatic brain injuries. Treating spasticity requires ongoing management and can include a number of different treatments given over many years. A relatively new treatment option for spasticity is botulinum neurotoxin, which is associated with a number of challenges, including appropriate patient selection, sequencing in the treatment continuum, and safe dosing and administration. The goal of this CME activity is to help clinicians understand the appropriate use of current and evolving treatment options for spasticity and ultimately improve their patients' outcomes.
. Target Audience
This activity is designed for neurologists, physiatrists,
and other clinicians who treat patients with spasticity.
Upon completion of this educational activity, the participant should be able to:
Discuss how to individually assess patients with spasticity to better implement strategies for management of their symptoms.
Determine when botulinum neurotoxin therapy may best benefit patients with spasticity.
Incorporate effective and safe dosing and administration strategies, including appropriate muscle selection, for botulinum neurotoxins in patients with spasticity.
Dr. Mari discloses that he has acted as a consultant for Medtronic, has participated on the advisory boards of Merz, US WorldMeds, and Ipsen, and has received grant funding from Allergan and Merz.
Dr. Moberg-Wolff discloses that she has served as a consultant for CNS Therapeutics and on the speakers bureau for US WorldMeds.
Rick Ricer, MD, physician reviewer, has no conflicts of interest to disclose.
Susan P. Tyler, MEd, CCMEP, FACEHP, has no conflicts of interest to disclose.
Elizabeth Friedenwald, MCM Education medical writer, has no conflicts of interest to disclose.
Kathleen Hines, MCM Education associate editorial director, has no conflicts of interest to disclose.
This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this Enduring Material Activity for a maximum of 0.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
University of Cincinnati
Continuing Medical Education
College of Medicine
3225 Eden Avenue, G24 Wherry Hall
Cincinnati, OH 45267
TERM OF OFFERING
This activity has a release date of October 22, 2012 and is valid for 1 year. Requests for credit must be received no later than October 22, 2013.
A review committee has agreed that this material can be completed in 30 minutes. This estimated study time in turn has determined the credit hours being offered.
INSTRUCTIONS FOR PARTICIPATING IN THIS ACTIVITY AND OBTAINING CME CREDIT
There are no fees for participating in and receiving CME credit for this online educational activity. By reviewing the course content and successfully completing the post-test and evaluation, clinicians are entitled to receive credit. The statement of credit will be available to print from your user history page.
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the post-test and activity evaluation
- Clinicians who successfully complete the post-test and evaluation will receive a CME certificate; successful completion is defined as a cumulative score of at least 80% correct
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation
ESTIMATED TIME TO COMPLETE
Commercial Support Statements
This activity is supported by an independent educational grant from Allergan, Inc.
Commercial Support Guidelines
If any activity is supported by funds from a commercial source such as a pharmaceutical company or an equipment manufacturer it is very important that the Standards for Commercial Support are followed. In general, commercial entities may support CME activities through unrestricted grants. A commercial supporter may not exert undue influence in the form of determining content, choosing speakers, directly paying honoraria to faculty or paying registration fees of attendees. An acknowledgement of any educational support from a commercial company must appear in program brochures, syllabi, and other program materials. Certificate Fee
The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of the University of Cincinnati, MCM Education, or the commercial supporter(s). Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product, device, or procedure mentioned.